DNA Test Interpretation
Executive summary, overall assessment, data quality, findings by health area, pharmacogenomics, nutrigenomics, disease risks, carrier status, recommended tests and red flags.
Sample report
What the AI DNA reports look like
Each report opens in the browser and prints as a clean A4 PDF with the clinic's logo and details. The examples below use synthetic data.
DNA + Blood Health Report
Overall status, gene and lab correlations, risk matrix, priority actions and monitoring plan.
Supplement plan
Recommendations with dose, timing, rationale and interactions, what to avoid, food sources and the re-test plan.
The full sample report, page by page
An 11-page DNA test interpretation made from synthetic test data, exactly as a clinic receives it. The patient name is a placeholder. Select a page to open it at full size.
-
1
Page 1 · Summary, overall assessment and data qualityClinic header, patient details, the executive summary, an overall assessment driven by APOE, LPA and CDKN2B-AS1, and the data-quality box: genotyping array, build GRCh37, call rate. -
2
Page 2 · Cardiovascular and lipid findingsFindings by area start with cardiovascular and lipid risk: APOE e3/e4, an elevated lipoprotein(a) allele and the 9p21.3 marker, each with risk level, evidence level and a recommendation. -
3
Page 3 · Pharmacogenomics: SLCO1B1, CYP2C19, CYP2C9Drug-response findings: SLCO1B1 decreased function for statins, CYP2C19 intermediate metabolizer for clopidogrel and PPIs, and CYP2C9 intermediate metabolizer. -
4
Page 4 · Warfarin, caffeine and other drug-response markersVKORC1 warfarin sensitivity, CYP1A2 caffeine metabolism, ABCG2, G6PD and ALDH2, a marker the array could not call, and the start of carrier status and monogenic markers. -
5
Page 5 · Carrier status, thrombophilia and lactaseHFE C282Y carrier status with confirmation advice, Factor V Leiden and prothrombin not detected, CFTR F508del not detected, and lactase non-persistence under nutrigenomics. -
6
Page 6 · Folate, vitamin D and omega-3 metabolismMTHFR C677T heterozygous, GC variant for lower vitamin D binding, FADS1 omega-3 conversion and FUT2 non-secretor status, then the metabolic and endocrine profile. -
7
Page 7 · Metabolic, neurochemistry and fitness traitsTCF7L2, FTO, PPARG and PNPLA3 metabolic findings, then COMT, SOD2 and GSTP1 in the cellular defence, neurochemistry and fitness section. -
8
Page 8 · Disease risks with genes and actionsACTN3, TNF, HLA-DQA1 and HERC2 findings, then disease risks with the genes behind them and concrete actions: atherosclerotic cardiovascular disease and late-onset Alzheimer's disease. -
9
Page 9 · Carrier status and pharmacogenomics tablesType 2 diabetes and haemochromatosis risk cards, the carrier status table (HFE carrier; CFTR, Factor V and prothrombin not detected) and the pharmacogenomics table with affected drugs. -
10
Page 10 · Nutrigenomics, traits and lifestyleDrug-response summary for CYP2C9, VKORC1 and CYP1A2, nutrigenomics for lactose, folate, vitamin D and omega-3, traits, and lifestyle recommendations tied to the findings. -
11
Page 11 · Follow-up tests, red flags and limitationsRecommended tests with reasons, red flags including an identity check between the patient profile and the laboratory requisition, the limitations of array genotyping and the disclaimer.
On every screen and on paper
In every report
- Your clinic's logo, name, address and contact details.
- Patient details, report date and language.
- Colour-coded risk and evidence levels.
- Limitations and a clear clinical disclaimer.
- Print-quality A4 PDF on any device, with selectable text.
Try it with your own patients
We will set up the clinic panel and walk you through the three modules.